Endometrial cancer risk in estrogen users after switching to estrogen-progestin therapy

Cancer Causes and Control

Volumn 18, Issue 9, 2007, Pages 1001-1007

  Chubak, Jessica ^a,b   Doherty, Jennifer A ^a   Cushing Haugen, Kara L ^a   Voigt, Lynda F ^a,b   Saltzman, Babette S ^a,b   Hill, Deirdre A ^c   Beresford, Shirley A A ^a,b   Weiss, Noel S ^a,b  

^a Fred Hutchinson Cancer Research Center   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

Author keywords

Endometrial neoplasms; Hormone replacement therapy; Pharmacoepidemiology

Indexed keywords

ESTROGEN; PROGESTERONE;

ADULT; AGED; ARTICLE; CANCER RISK; CONTROLLED STUDY; DATA ANALYSIS; ENDOMETRIUM CANCER; ESTROGEN THERAPY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL;

AGED; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; DRUG ADMINISTRATION SCHEDULE; ENDOMETRIAL NEOPLASMS; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; INTERVIEWS AS TOPIC; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGESTINS; RISK FACTORS;

EID: 34547730279     PISSN: 09575243     EISSN: 15737225     Source Type: Journal    
DOI: 10.1007/s10552-007-9040-6     Document Type: Article

References (25)

1. Cook LS, Weiss NS (2000) Endometrial cancer. In: Goldman MB, Hatch MC (eds) Women and health. Academic Press, San Diego, pp 916-931
2. Jick H, Watkins RN, Hunter JR et al (1979) Replacement estrogens and endometrial cancer. N Engl J Med 300(5):218-222
3. Lacey JV Jr, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C (2005) Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev 14(7):1724-1731
4. Newcomb PA, Trentham-Dietz A (2003) Patterns of postmenopausal progestin use with estrogen in relation to endometrial cancer (United States). Cancer Causes Control 14(2):195-201
5. Paganini-Hill A, Ross RK, Henderson BE (1989) Endometrial cancer and patterns of use of oestrogen replacement therapy: a cohort study. Br J Cancer 59(3):445-447
6. Shapiro S, Kelly JP, Rosenberg L et al (1985) Risk of localized and widespread endometrial cancer in relation to recent and discontinued use of conjugated estrogens. N Engl J Med 313(16):969-972
7. Weiss NS, Szekely DR, English DR, Schweid AI (1979) Endometrial cancer in relation to patterns of menopausal estrogen use. Jama 242(3):261-264
8. Finkle WD, Greenland S, Miettinen OS, Ziel HK (1995) Endometrial cancer risk after discontinuing use of unopposed conjugated estrogens (California, United States). Cancer Causes Control 6(2):99-102
9. Hulka BS, Fowler WC Jr, Kaufman DG et al (1980) Estrogen and endometrial cancer: cases and two control groups from North Carolina. Am J Obstet Gynecol 137(1):92-101
10. Pettersson B, Adami HO, Persson I, Bergstrom R, Lindgren A, Johansson ED (1986) Climacteric symptoms and estrogen replacement therapy in women with endometrial carcinoma. Acta Obstet Gynecol Scand 65(1):81-87
11. Jain MG, Rohan TE, Howe GR (2000) Hormone replacement therapy and endometrial cancer in Ontario, Canada. J Clin Epidemiol 53(4):385-391
12. Rubin GL, Peterson HB, Lee NC, Maes EF, Wingo PA, Becker S (1990) Estrogen replacement therapy and the risk of endometrial cancer: remaining controversies. Am J Obstet Gynecol 162(1):148-154
13. Pike MC, Peters RK, Cozen W et al (1997) Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst 89(15):1110-1116
14. Weiderpass E, Adami HO, Baron JA et al (1999) Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 91(13):1131-1137
15. Beresford SA, Weiss NS, Voigt LF, McKnight B (1997) Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 349(9050):458-461
16. Hill DA, Weiss NS, Beresford SA et al (2000) Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 183(6):1456-1461
17. Doherty JA, Cushing-Haugen KL, Siebold B et al (2007) Long-term continuous combined use of postmenopausal hormone therapy and endometrial cancer risk. Am J Obstet Gynecol 197 (in press)
18. Marchbanks PA, McDonald JA, Wilson HG et al (2002) The NICHD women's contraceptive and reproductive experiences study: methods and operational results. Ann Epidemiol 12(4):213-221
19. Beresford SA, Coker AL (1989) Pictorially assisted recall of past hormone use in case-control studies. Am J Epidemiol 130(1):202-205
20. McKnight B, Cook LS, Weiss NS (1999) Logistic regression analysis for more than one characteristic of exposure. Am J Epidemiol 149(11):984-992
21. Ness RB, Buhari A, Gutai J, Kuller LH (2000) Reproductive history in relation to plasma hormone levels in healthy post-menopausal women. Maturitas 35:149-157
22. Figueroa-Casas PR, Ettinger B, Delgado E, Javkin A, Vieder C (2001) Reversal by medical treatment of endometrial hyperplasia caused by estrogen replacement therapy. Menopause 8(6):420-423
23. Ferenczy A, Gelfand M (1989) The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol 160(1):126-131
24. Gambrell RD Jr (1997) Strategies to reduce the incidence of endometrial cancer in postmenopausal women. Am J Obstet Gynecol 177(5):1196-1204, discussion 204-207
25. Woodruff JD, Pickar JH (1994) Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone. The menopause study group. Am J Obstet Gynecol 170(5 Pt 1):1213-1223